Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.
Acute coronary syndromes
Biomarker
Cardiac disease
Congestive heart failure
Coronary artery disease
Inflammation
Ischemic heart disease
Myocardial infarction
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
23
02
2021
accepted:
02
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
ppublish
Résumé
This review summarizes the published literature referring to the use and validity of the biomarker soluble urokinase plasminogen activator receptor (suPAR) when used for the assessment of patients with cardiac diseases. It is measured by enzyme-linked immunosorbent assay (ELISA) in plasma samples. In cardiology a cut-off value range of 3.5 - 4.5 ng/mL has been commonly utilized. Different cut-off values may be applied based on the measuring kit used, the patient population and the clinical setting. A PubMed/Medline search was conducted aiming to identify all publications relevant to the use of suPAR in patients with cardiac diseases. A total of 39 studies were included in this review. suPAR as a marker of inflammation has been used more extensively in recent years, alone or in combination with other biomarkers of inflammation and cardiac pathology in the assessment of patients with acute and chronic cardiac diseases. suPAR is closely related to the pathophysiology of cardiac disease, and a number of publications encourages its use as a valuable biomarker in the assessment of patients presenting to the cardiology service. It may be most valuable in the risk assessment of patients with acute coronary syndromes and congestive heart failure, as suPAR elevation may be an independent predictor of mortality in these conditions. In conclusion, among several biomarkers used for clinical entities with underlying inflammatory pathophysiology including cardiac diseases, suPAR is a novel attractive index for the prognostic risk stratification of cardiac patients. More research is warranted to confirm its diagnostic and prognostic validity, alone or combined with other cardiac and inflammatory biomarkers.
Identifiants
pubmed: 33854652
doi: 10.14740/jocmr4459
pmc: PMC8016523
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
133-142Informations de copyright
Copyright 2021, Velissaris et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Am Heart Assoc. 2014 Oct 23;3(5):e001118
pubmed: 25341887
J Periodontol. 2020 Oct 22;:
pubmed: 33091149
Transl Res. 2013 Nov;162(5):287-96
pubmed: 23916811
Eur J Heart Fail. 2014 Apr;16(4):377-83
pubmed: 24464777
Acta Clin Belg. 2021 Feb;76(1):79-84
pubmed: 31434557
Minerva Med. 2018 Dec;109(6):443-450
pubmed: 29652038
Thromb Haemost. 2019 Dec;119(12):1947-1955
pubmed: 31659734
Circ Cardiovasc Qual Outcomes. 2017 Mar;10(3):
pubmed: 28280039
Can J Cardiol. 2015 Oct;31(10):1293-302
pubmed: 26118447
Ann Card Anaesth. 2016 Apr-Jun;19(2):214-6
pubmed: 27052059
Int J Antimicrob Agents. 2015 Dec;46 Suppl 1:S33-4
pubmed: 26603640
Atherosclerosis. 2014 Nov;237(1):60-6
pubmed: 25222341
Eur J Endocrinol. 2016 Jun;174(6):745-53
pubmed: 26951602
Eur J Clin Invest. 2017 Sep;47(9):638-648
pubmed: 28683166
Eur J Clin Invest. 2013 May;43(5):457-68
pubmed: 23517378
Intensive Care Med. 2012 Sep;38(9):1418-28
pubmed: 22706919
Infect Dis Ther. 2020 Sep;9(3):407-416
pubmed: 32399855
HIV Med. 2016 May;17(5):350-7
pubmed: 26365671
Biomarkers. 2018 Dec;23(8):773-780
pubmed: 30041555
Am J Cardiol. 2012 Dec 15;110(12):1756-63
pubmed: 22981263
Dis Markers. 2017;2017:4719403
pubmed: 29109596
Panminerva Med. 2020 Sep;62(3):135-142
pubmed: 32309918
J Atr Fibrillation. 2018 Apr 30;10(6):1801
pubmed: 29988279
PLoS One. 2013;8(3):e58506
pubmed: 23516493
Biomolecules. 2019 Mar 18;9(3):
pubmed: 30889909
Kidney Blood Press Res. 2018;43(3):664-672
pubmed: 29734173
Int J Cardiol. 2013 Sep 10;167(6):2904-11
pubmed: 22909410
N Engl J Med. 2015 Nov 12;373(20):1916-25
pubmed: 26539835
Eur J Intern Med. 2017 Oct;44:31-38
pubmed: 28579310
Can J Cardiol. 2016 Dec;32(12):1462-1469
pubmed: 27499378
Heart Vessels. 2017 Nov;32(11):1327-1336
pubmed: 28589505
Atherosclerosis. 2011 May;216(1):237-43
pubmed: 21354571
PLoS One. 2017 Jan 30;12(1):e0170546
pubmed: 28135310
Stroke. 2014 Jan;45(1):18-23
pubmed: 24253546
Arch Med Sci. 2019 Jan;15(1):72-77
pubmed: 30697255
J Am Heart Assoc. 2020 Mar 3;9(5):e015457
pubmed: 32089048
JACC Heart Fail. 2017 Apr;5(4):268-277
pubmed: 28359415
Ther Hypothermia Temp Manag. 2015 Jun;5(2):89-94
pubmed: 25695339
Dis Markers. 2009;27(3):157-72
pubmed: 19893210
Atherosclerosis. 2015 Mar;239(1):55-60
pubmed: 25574858
Resuscitation. 2014 Nov;85(11):1562-7
pubmed: 25193800
Clin Chem. 2013 Nov;59(11):1621-9
pubmed: 23842203
Atherosclerosis. 2017 Sep;264:108-114
pubmed: 28728756
J Arrhythm. 2017 Oct;33(5):469-474
pubmed: 29021852
Clin Res Cardiol. 2019 Dec;108(12):1386-1393
pubmed: 30989318
Open Heart. 2018 Jan 13;5(1):e000743
pubmed: 29387432
Eur J Prev Cardiol. 2020 Apr;27(6):570-578
pubmed: 31718257
PLoS One. 2014 Jul 11;9(7):e101522
pubmed: 25014213